Therapy Areas: Respiratory
Sosei updates on immuno-oncology clinical programme with AstraZeneca
8 February 2018 -

Sosei Group Corporation (TYO: 4565) has dosed the first patient in an expansion cohort of the Phase 1b segment of its Phase 1 study in advanced solid tumours being conducted in collaboration with AstraZeneca (LON: AZN), the company announced on Thursday.

The two companies are also expected to start a new clinical study including AZD4635 to investigate novel combination therapies in EGFRm non-small cell lung cancer in the first quarter of 2018.

AZD4635 is a potent and selective, orally available, small molecule adenosine A2A receptor (A2AR) antagonist that was discovered by Sosei's subsidiary, Heptares Therapeutics. It was licensed to AstraZeneca in 2015.

The Phase 1 trial is investigating AZD4635 in patients with advanced solid malignancies. The primary objective is to determine the maximum tolerated dose of AZD4635 as a monotherapy, as well as in combination with AstraZeneca's anti-PD-L1 antibody durvalumab.

Sosei expects the Phase 1b expansion cohort in advanced solid tumours, which is sponsored by AstraZeneca, to complete in the second half of 2019.

Login
Username:

Password: